RXRX
Market cap | $2.17 Billion |
---|---|
Enterprise Value | $1.92 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.62 |
Beta | 0.0 |
Outstanding Shares | 230,273,797 |
Avg 30 Day Volume | 5,339,196 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -6.13 |
---|---|
PEG | -15.36 |
Price to Sales | - |
Price to Book Ratio | 9.42 |
Enterprise Value to Revenue | 41.61 |
Enterprise Value to EBIT | -5.11 |
Enterprise Value to Net Income | -6 |
Total Debt to Enterprise | 0.03 |
Debt to Equity | 0.13 |
No data
No data
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...